AstraZeneca initiated with a Buy at Guggenheim Guggenheim analyst Seamus Fernandez started with a Buy rating and 7,018p price target, citing his belief that the company’s new product launches in oncology and severe asthma can drive the fastest sales and EPS growth in global pharma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.